Myelodysplasia. New Engl J Med 1999;340:1649–60., .
Myelodysplastic syndrome is not merely “preleukemia.”Blood 2002;100:791–8., , , et al.
Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006;24:5358–65., , , et al.
First report of national estimates of the incidence of myelodysplastic syndromes and chronic myeloproliferative disorders from the U.S. SEER Program. Blood 2006;108:77a., , , et al.
Clinical and economic consequences of myelodysplastic syndromes in the United States: an analysis of the Medicare database. Blood 2008;112:237., , .
Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res 1999;23:57–62., , , et al.
Atomic bomb radiation increases the risk of MDS. Leuk Res 2001;25:S13., , , et al.
Therapy-related myelodysplastic syndromes. Semin Hematol 1996;33:256–73., .
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 2003;21:897–906., , , et al.
Jowitt S, et al. of the UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003;120:187–200., ,
A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000;14:2–8., .
Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004;18:1176–99..
The role of apoptosis, proliferation, and the BCL2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932–8., , , et al.
Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005;166:557–63., , , et al.
Can molecular profiling of cytogenetic subgroups draw a roadmap for individualizing therapy in myelodysplastic syndromes?Future Oncol 2006;2:407–15., , , et al.
Correlation of cytogenetic findings with morphology, clinical course, and prognosis in 2124 patients with MDS. Blood 2005;106:232a., , , et al.
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110:4385–95., , , et al.
The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292–302., , .
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335–9., , , et al.
A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987;327:430–32., , , et al.
Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature 1987;330:186–8., , , et al.
SOCS1 methylation predicts a high risk of acute leukemic transformation in primary myelodysplastic syndrome. Blood 2006;108:742a., , , et al.
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189–99., , , et al.
FAB classification of myelodysplastic syndromes: merits and controversies. Ann Hematol 1995;71:3–11., , , et al.
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91:1596–604., , , et al.
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–88., , , et al.
Application of the international scoring system for myelodysplasia to MD Anderson patients. Blood 1997;90:2843–4., , , et al.
Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med 2005;352:536–8., .
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351–61., , , et al.
Hyoplastic myelodysplastic syndrome – a clinical, morphologic, or genetic diagnosis?Cancer Genet Cytogenet 2002;138:85–8., .
Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia 2006;20:458–62., , , et al.
Clinical clusters of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009;27:754–62., , , et al.
Chronic myelomonocytic leukemia: lost in classification?Hematol Oncol 2005;23:26–33..
Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006;91:719–20., , , et al.
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61–4., , , et al.
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96:3671–4., , , et al.
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419–25., , , et al.
Efficacy and safety of Deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood 2008;112:235., , , et al.
Iron chelation with Deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008;112:236., , , et al.
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003;120:1037–46., , , et al.
Prognostic factors and response duration in 419 MDS treated with erythropoietin ± G-CSF: The GFM experience. Blood 2006;108:158a., , , et al.
Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005;106:803–11., , , et al.
The incidence and impact of thrombocytopenia in myelodysplastic syndrome (MDS). Blood 2006;108:739a., , , et al.
Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma 2006;47:2049–54., , , et al.
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007;357:2237–47., , , et al.
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006;355:2054., , , et al.
Phase 1/2 study of AMG 531 in thrombocytopenic patients (Pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment. Blood 2007;110:81a., , , et al.
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002;137:156–63., , , et al.
A prospective, randomized, phase II study of horse antithymocyte globulin vs rabbit antithymoycte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndrome. Leukemia 2004;18:460–5., , , et al.
European multi-centre study on the use of anti-thymocyte globulin in the treatment of myelodysplastic syndromes. Blood 2005;106:707a., , , et al.
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505–11., , , et al.
Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation. Blood 1995;85:283–90., , , et al.
Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352:549–57., , , et al.
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456–65., , , et al.
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008;111:86–93., , , et al.
Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. Nat Clin Pract Oncol 2005;2 Suppl 1:S24–9..
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20:2429–40., , , et al.
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009;10:223–32., , , et al.
An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005;84:9–17., , , et al.
Decitabine improves patient outcome in myelodysplastic syndrome. Cancer 2006;106:1794–803., , , et al.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52–7., , , et al.
Preliminary results of a phase II study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndrome (MDS). Blood 2007;110:434a., , , et al.
Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS Study Groups. Blood 2008;112:90., , , et al.
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895–902., , , et al.
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitdine. Leuk Lymphoma 2008;49:650–1., , , et al.
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006;24:2465–72., , , et al.
Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006;24:2456–64., , , et al.
Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657. Blood 2004;104:561–4., , , et al.
Hematologic improvement (HI) by TLK199 (Telintra™), a novel glutathione analog, in myelodysplastic syndrome: phase 2 study results. Blood 2005;106:708a., , , et al.
A phase I trial of the small molecule pan-BCL2 family inhibitor Obatoclax (GX15–070) administered by 24 hour infusion every 2 weeks to patients with myeloid malignancies and chronic lymphocytic leukemia (CLL). Blood 2006;108:750a., , , et al.
Oral (po) and intravenous (iv) clofarabine for patients (pts) with myelodysplastic syndrome (MDS). Blood 2008;112:89., , , et al.
Survival benefit with decitabine compared to historical experience with intensive chemotherapy in patients with high risk myelodysplastic syndrome (MDS). Blood 2006;108:749a., , , et al.
High-dose chemotherapy in high-risk myelodysplastic syndrome – covariate-adjusted comparison of five regimens. Cancer 2001;92:1999–2015., , , et al.
Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res 2000;24:653–63., .
Bone marrow transplantation from HLA-identical siblings as treatment for myelodsyplasia. Blood 2002;200:1997–2004., , , et al.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–85., , , et al.
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–46., , , et al.
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002;100:1201–7., , , et al.